Insider Selling: Alexion Pharmaceuticals, Inc. (ALXN) EVP Sells 1,625 Shares of Stock
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) EVP Julie O’neill sold 1,625 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $119.83, for a total transaction of $194,723.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at $117.92 on Friday. The company has a current ratio of 3.10, a quick ratio of 2.62 and a debt-to-equity ratio of 0.34. The company has a market cap of $25,517.75, a P/E ratio of 60.16, a P/E/G ratio of 1.07 and a beta of 1.13. Alexion Pharmaceuticals, Inc. has a fifty-two week low of $96.18 and a fifty-two week high of $149.34.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.09 by $0.39. The business had revenue of $909.70 million during the quarter, compared to analysts’ expectations of $880.38 million. Alexion Pharmaceuticals had a net margin of 12.48% and a return on equity of 12.94%. The firm’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period last year, the company posted $1.26 earnings per share. analysts anticipate that Alexion Pharmaceuticals, Inc. will post 6.12 EPS for the current year.
Several hedge funds have recently bought and sold shares of ALXN. Delpha Capital Management LLC acquired a new stake in Alexion Pharmaceuticals in the fourth quarter valued at approximately $102,000. Valeo Financial Advisors LLC acquired a new stake in Alexion Pharmaceuticals in the third quarter valued at approximately $147,000. CNB Bank acquired a new stake in Alexion Pharmaceuticals in the fourth quarter valued at approximately $150,000. Dupont Capital Management Corp acquired a new stake in Alexion Pharmaceuticals in the third quarter valued at approximately $156,000. Finally, BT Investment Management Ltd acquired a new stake in Alexion Pharmaceuticals in the third quarter valued at approximately $165,000. Institutional investors and hedge funds own 95.38% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.watchlistnews.com/insider-selling-alexion-pharmaceuticals-inc-alxn-evp-sells-1625-shares-of-stock/1905186.html.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.